The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study

The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study

Introduction: Thrombocytopenia, a hallmark of cytopenic myelofibrosis (MF), is associated with poor survival and quality of life impairment. Patients with MF and moderate or severe thrombocytopenia (platelet counts

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2021-11, Vol.138 (Supplement 1), p.3628-3628
Hauptverfasser: Palmer, Jeanne M., Mesa, Ruben A., Oh, Stephen T., Rampal, Raajit, Buckley, Sarah A, Roman-Torres, Karisse, Verstovsek, Srdan, Mascarenhas, John, Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Harrison, Claire N., Bose, Prithviraj, Craig, Adam R, Gerds, Aaron T.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction: Thrombocytopenia, a hallmark of cytopenic myelofibrosis (MF), is associated with poor survival and quality of life impairment. Patients with MF and moderate or severe thrombocytopenia (platelet counts
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2021-144505